DK1964852T3 - Anti-ilt7-antistof - Google Patents

Anti-ilt7-antistof

Info

Publication number
DK1964852T3
DK1964852T3 DK06842945.5T DK06842945T DK1964852T3 DK 1964852 T3 DK1964852 T3 DK 1964852T3 DK 06842945 T DK06842945 T DK 06842945T DK 1964852 T3 DK1964852 T3 DK 1964852T3
Authority
DK
Denmark
Prior art keywords
ilt7 antibody
ilt7
antibody
Prior art date
Application number
DK06842945.5T
Other languages
English (en)
Inventor
Yumiko Kamogawa
Minkwon Cho
Naoko Arai
Koji Ishida
Original Assignee
Sbi Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbi Biotech Co Ltd filed Critical Sbi Biotech Co Ltd
Application granted granted Critical
Publication of DK1964852T3 publication Critical patent/DK1964852T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
DK06842945.5T 2005-12-20 2006-12-20 Anti-ilt7-antistof DK1964852T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005366465 2005-12-20
PCT/JP2006/325391 WO2007072866A1 (ja) 2005-12-20 2006-12-20 抗ｉｌｔ７抗体

Publications (1)

Publication Number Publication Date
DK1964852T3 true DK1964852T3 (da) 2013-07-08

Family

ID=38188642

Family Applications (3)

Application Number Title Priority Date Filing Date
DK12168586.1T DK2532681T3 (da) 2005-12-20 2006-12-20 Anti-ILT7-antistof
DK06842945.5T DK1964852T3 (da) 2005-12-20 2006-12-20 Anti-ilt7-antistof
DK14186905.7T DK2913343T3 (da) 2005-12-20 2006-12-20 Anti-ILT7-antistof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK12168586.1T DK2532681T3 (da) 2005-12-20 2006-12-20 Anti-ILT7-antistof

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14186905.7T DK2913343T3 (da) 2005-12-20 2006-12-20 Anti-ILT7-antistof

Country Status (29)

Country Link
US (6) US8084585B2 (da)
EP (4) EP3441403A1 (da)
JP (2) JP5020828B2 (da)
KR (3) KR101526934B1 (da)
CN (4) CN110776566A (da)
AU (1) AU2006328470B2 (da)
BR (1) BRPI0620141A2 (da)
CA (2) CA2634116C (da)
CY (3) CY1114227T1 (da)
DK (3) DK2532681T3 (da)
ES (3) ES2526079T3 (da)
HK (4) HK1124347A1 (da)
HR (2) HRP20130494T1 (da)
HU (1) HUE039865T2 (da)
IL (1) IL192266A (da)
LT (1) LT2913343T (da)
ME (1) ME02111B (da)
MX (1) MX2008007682A (da)
NZ (3) NZ616992A (da)
PL (3) PL2913343T3 (da)
PT (3) PT2913343T (da)
RS (2) RS53752B1 (da)
RU (2) RU2456298C2 (da)
SG (2) SG10201602095PA (da)
SI (3) SI1964852T1 (da)
TR (1) TR201816574T4 (da)
UA (1) UA97946C2 (da)
WO (1) WO2007072866A1 (da)
ZA (1) ZA200805850B (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
AU2010319531A1 (en) * 2009-11-10 2012-05-24 Amgen Inc. Anti-c-MPL antibodies
US8945569B2 (en) 2009-11-19 2015-02-03 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
TWI504408B (zh) 2010-02-24 2015-10-21 Immunogen Inc 葉酸受體１抗體類和免疫共軛物類及彼等之用途
EP3085387A1 (en) * 2010-04-26 2016-10-26 Abraxis BioScience, LLC Sparc binding antibodies and uses thereof
KR20200039843A (ko) 2011-04-01 2020-04-16 이뮤노젠 아이엔씨 Folr1 암 치료의 효능을 증가시키기 위한 방법
WO2013142300A2 (en) * 2012-03-20 2013-09-26 Biogen Idec Ma Inc. Jcv neutralizing antibodies
CA2867902C (en) 2012-03-20 2023-09-26 Biogen Idec Ma Inc. Jcv neutralizing antibodies
CN111499755A (zh) * 2012-08-03 2020-08-07 丹娜法伯癌症研究院 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
KR20150046316A (ko) 2012-08-31 2015-04-29 이뮤노젠 아이엔씨 엽산 수용체 1의 검출을 위한 진단성 검정 및 키트
EP3925980A1 (en) 2013-08-30 2021-12-22 ImmunoGen, Inc. Antibodies and assays for detection of folate receptor 1
WO2015051159A1 (en) * 2013-10-02 2015-04-09 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
CA2934604A1 (en) * 2013-12-24 2015-07-02 Astellas Pharma Inc. Novel anti-human bdca-2 antibody
HUE061672T2 (hu) 2014-11-12 2023-08-28 Seagen Inc Glikán-interakcióban lévõ vegyületek és felhasználási módszerek
US10722592B2 (en) * 2015-03-18 2020-07-28 Seattle Genetics, Inc. CD48 antibodies and conjugates thereof
PT3313884T (pt) * 2015-06-29 2021-02-25 Immunogen Inc Anticorpos anti-cd123 e conjugados e derivados dos mesmos
KR20180053319A (ko) 2015-09-17 2018-05-21 이뮤노젠 아이엔씨 항-folr1 면역접합체를 포함하는 치료제 조합
CN116217729A (zh) 2015-11-12 2023-06-06 思进公司 聚糖相互作用化合物及使用方法
EP3377079A1 (en) * 2015-11-19 2018-09-26 Abbvie Stemcentrx LLC Novel anti-emr2 antibodies and methods of use
CN114948213A (zh) 2016-01-26 2022-08-30 网络牙科(美国)公司 自动牙科治疗系统
US20190031780A1 (en) * 2016-01-27 2019-01-31 Siamab Therapeutics, Inc. Compositions and methods for targeting cancer stem cells
MX2018010445A (es) * 2016-03-01 2019-10-17 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos especificos del receptor de poliovirus humano (rvp).
SG11201807523PA (en) * 2016-03-10 2018-09-27 Viela Bio Inc Ilt7 binding molecules and methods of using the same
CN109563158B (zh) 2016-04-04 2022-08-09 比奥贝拉蒂美国公司 抗补体因子bb抗体以及其用途
EP3589319A4 (en) 2017-03-03 2021-07-14 Seagen Inc. COMPOUNDS INTERACTING WITH GLYCAN AND METHODS OF USE
KR20200042937A (ko) * 2017-08-30 2020-04-24 페인스 테라퓨틱스 인코포레이티드 항-lag-3 항체 및 이의 용도
JP7369121B2 (ja) 2017-10-11 2023-10-25 バイオベラティブ・ユーエスエイ・インコーポレイテッド 補体活性を誘発する方法
AR113696A1 (es) * 2017-11-17 2020-06-03 Merck Sharp & Dohme Anticuerpos específicos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos
JP2021511068A (ja) * 2017-12-20 2021-05-06 ラディミューン セラピュティックス， インク．Ｒａｄｉｍｍｕｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｃｅｎｔｒｉｎ−１に対する抗体、作製方法、及びその使用
CN111542546B (zh) * 2018-01-18 2022-08-16 四川科伦博泰生物医药股份有限公司 抗lag-3抗体及其用途
TW202003576A (zh) * 2018-05-10 2020-01-16 美商艾博視訊有限公司 活化cd40之單株抗體及其用途
EP4069288A4 (en) * 2019-12-06 2024-01-17 Viela Bio Inc TREATMENT METHODS USING ILT7 BINDING PROTEINS
AU2021261257A1 (en) 2020-04-20 2022-12-22 Genzyme Corporation Humanized anti-complement factor Bb antibodies and uses thereof
AU2022270101A1 (en) * 2021-05-04 2023-10-05 Viela Bio, Inc. Methods of treatment of autoimmune disorders using ilt7 binding proteins
WO2024026388A1 (en) 2022-07-27 2024-02-01 Viela Bio, Inc. Formulations comprising an immunoglobulin-like transcript 7 (ilt7)-binding protein
CN116948032B (zh) * 2023-09-19 2023-12-12 汇智生物技术(苏州)有限公司 人源cd4单克隆抗体及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
DK1156823T3 (da) * 1999-02-12 2009-01-19 Scripps Research Inst Fremgangsmåder til behandling af tumorer og metastaser ved anvendelse af en kombination af anti-angiogene terapier og immunoterapier
WO2001058956A2 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US6897067B2 (en) * 2000-11-03 2005-05-24 Regents Of The University Of Michigan Surface transfection and expression procedure
AU2002318944A1 (en) 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
US7485713B2 (en) * 2001-10-13 2009-02-03 Asterion Limited Polypeptides comprising growth hormone receptor extracellular domain and glycosylphosphatidylinositol
NZ554740A (en) * 2002-05-24 2009-01-31 Schering Corp Neutralizing human anti-IGFR antibody
AU2003252328A1 (en) 2002-08-01 2004-02-23 Ginkgo Biomedical Research Institute Co., Ltd. Method of detecting mouse interferon-producing cells
WO2004023973A2 (en) * 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
EP1664762A4 (en) 2003-09-03 2008-08-13 Us Gov Health & Human Serv METHODS OF IDENTIFICATION, DIAGNOSIS AND PREDICTION FOR LYMPHOMES SURVIVAL
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound

Also Published As

Publication number Publication date
EP1964852B1 (en) 2013-04-17
IL192266A0 (en) 2008-12-29
US8084585B2 (en) 2011-12-27
KR101585532B1 (ko) 2016-01-14
EP3441403A1 (en) 2019-02-13
EP2532681A1 (en) 2012-12-12
CN105111311B (zh) 2019-10-18
SI2532681T1 (sl) 2015-03-31
RU2008129715A (ru) 2010-01-27
KR20140053232A (ko) 2014-05-07
KR101526934B1 (ko) 2015-06-26
KR101624587B1 (ko) 2016-05-26
SI1964852T1 (sl) 2013-09-30
ES2416716T3 (es) 2013-08-02
HK1179638A1 (en) 2013-10-04
CN110776566A (zh) 2020-02-11
NZ616992A (en) 2015-07-31
PL1964852T3 (pl) 2013-09-30
CA2994756A1 (en) 2007-06-28
AU2006328470B2 (en) 2012-08-16
US20120135003A1 (en) 2012-05-31
EP1964852A1 (en) 2008-09-03
US20170204179A1 (en) 2017-07-20
JPWO2007072866A1 (ja) 2009-06-04
JP5420688B2 (ja) 2014-02-19
US20130259872A1 (en) 2013-10-03
CY1121294T1 (el) 2020-05-29
EP1964852A4 (en) 2010-02-24
ZA200805850B (en) 2009-04-29
NZ569910A (en) 2012-06-29
DK2913343T3 (da) 2018-11-26
CY1114227T1 (el) 2016-08-31
ME02111B (me) 2015-10-20
CN101379089B (zh) 2013-08-07
ES2526079T3 (es) 2015-01-05
US20160130343A1 (en) 2016-05-12
US8470992B2 (en) 2013-06-25
JP2012143232A (ja) 2012-08-02
MX2008007682A (es) 2008-10-23
PT2913343T (pt) 2018-11-21
KR20150031485A (ko) 2015-03-24
HRP20130494T1 (en) 2013-08-31
CA2634116A1 (en) 2007-06-28
CN103360492A (zh) 2013-10-23
LT2913343T (lt) 2018-11-26
TR201816574T4 (tr) 2018-11-21
PL2532681T3 (pl) 2015-03-31
AU2006328470A2 (en) 2008-10-09
PL2913343T3 (pl) 2019-03-29
EP2913343B1 (en) 2018-08-08
HK1218126A1 (zh) 2017-02-03
RS53752B1 (en) 2015-06-30
EP2913343A1 (en) 2015-09-02
HRP20141226T1 (hr) 2015-02-27
RU2599450C2 (ru) 2016-10-10
HK1214603A1 (zh) 2016-07-29
RU2012112046A (ru) 2013-10-10
US20090280128A1 (en) 2009-11-12
BRPI0620141A2 (pt) 2011-11-01
CN105111311A (zh) 2015-12-02
RS52860B (en) 2013-12-31
SI2913343T1 (sl) 2019-01-31
PT1964852E (pt) 2013-07-10
NZ599683A (en) 2013-11-29
SG10201602095PA (en) 2016-05-30
JP5020828B2 (ja) 2012-09-05
IL192266A (en) 2014-09-30
DK2532681T3 (da) 2015-01-05
AU2006328470A1 (en) 2007-06-28
EP2532681B1 (en) 2014-10-01
SG170749A1 (en) 2011-05-30
HK1124347A1 (en) 2009-07-10
RU2456298C2 (ru) 2012-07-20
KR20080090430A (ko) 2008-10-08
CA2634116C (en) 2018-03-27
CA2994756C (en) 2020-10-27
UA97946C2 (ru) 2012-04-10
ES2699428T3 (es) 2019-02-11
PT2532681E (pt) 2014-12-23
WO2007072866A1 (ja) 2007-06-28
US20200339682A1 (en) 2020-10-29
CY1116031T1 (el) 2017-01-25
HUE039865T2 (hu) 2019-02-28
CN101379089A (zh) 2009-03-04

Similar Documents

Publication Publication Date Title
NO20076607L (no) TWEAK - bindende antistoff
DK1964852T3 (da) Anti-ilt7-antistof
CY2016030I2 (el) Αντισωματα εναντι της il-17
NO20071430L (no) Anti-OX4OL antistoffer
ATE408603T1 (de) Pyrazolylcarboxanilide
CR9974A (es) Gavión
DE502006003394D1 (de) Lehnenklappung
DE602006012066D1 (de) Daraus
DE502006005667D1 (de) Gelenklager
ATE549324T1 (de) Tetrahydrobenzoxazine
DE602005006405D1 (de) Maisabstreifer
DE502006006857D1 (de) Wingungserregern
DE502006005768D1 (de) Hydrolysestabilisatorformulierungen
DE602005009179D1 (de) Telekommunikatiosverbinder
DE112006002964A5 (de) Zweirichtungsreflektanzverteilungsmessgerät
DE502005005839D1 (de) Feldgeerät
DE502006001397D1 (de) Lagerbuchse
DE602005003547D1 (de) Fahrradantriebsnabe
ATE485368T1 (de) Hiv - impfung
DE502006004302D1 (de) Verschlusskappe
DE502006001004D1 (de) Hydrolager
DE102005052834B8 (de) Punktschweißklebverbindung
DE502006003210D1 (de) Nohydrogenpolysiloxanen
DE602005008023D1 (de) Originalitätssprühkappe
AT501523A3 (de) Estrich